-
Posted by
Two Blokes Jul 26 -
Filed in
Stock
-
2 views
GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (LLY 0.84%) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help. But a growing number of studies suggest that they could be useful in indications beyond diabetes and weight loss.
